Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Diversity & Inclusion Financing Business Strategies

Medtech Companies Face Challenges And Choices When Going Public

  • Analysis

Executive Summary

In a panel discussion at The Medtech Conference, hosted by AdvaMed, CEOs discussed the challenges, benefits and technicalities surrounding an IPO.

You may also be interested in...



Investor Eye: Novalis Embraces Early Investment And Enabling Technology

Novalis Biotech employs early targeted investments to produce returns, focusing on enabling technologies and risky ventures in diagnostics and digital health.

Inivata Continues Trials Of Its Liquid Biopsy Platform

The partnership with the Princess Margaret Cancer Center will support two studies of liquid biopsy testing for lung cancer.

Exec Chat: Abionic Is Accelerating Diagnostics To Save Lives

Abionic CEO Nicolas Durand explains how Abionic is filling unmet needs in diagnostics and the Swiss company’s plans for expansion.

Table

View full table

Topics

Tags:
Diversity & Inclusion Financing Business Strategies
UsernamePublicRestriction

Register

MT144567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By